Your browser doesn't support javascript.
loading
Mucosal adenovirus vaccine boosting elicits IgA and durably prevents XBB.1.16 infection in nonhuman primates.
Gagne, Matthew; Flynn, Barbara J; Andrew, Shayne F; Marquez, Josue; Flebbe, Dillon R; Mychalowych, Anna; Lamb, Evan; Davis-Gardner, Meredith E; Burnett, Matthew R; Serebryannyy, Leonid A; Lin, Bob C; Ziff, Zohar E; Maule, Erin; Carroll, Robin; Naisan, Mursal; Jethmalani, Yogita; Pessaint, Laurent; Todd, John-Paul M; Doria-Rose, Nicole A; Case, James Brett; Dmitriev, Igor P; Kashentseva, Elena A; Ying, Baoling; Dodson, Alan; Kouneski, Katelyn; O'Dell, Sijy; Wali, Bushra; Ellis, Madison; Godbole, Sucheta; Laboune, Farida; Henry, Amy R; Teng, I-Ting; Wang, Danyi; Wang, Lingshu; Zhou, Qiong; Zouantchangadou, Serge; Van Ry, Alex; Lewis, Mark G; Andersen, Hanne; Kwong, Peter D; Curiel, David T; Roederer, Mario; Nason, Martha C; Foulds, Kathryn E; Suthar, Mehul S; Diamond, Michael S; Douek, Daniel C; Seder, Robert A.
  • Gagne M; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Flynn BJ; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Andrew SF; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Marquez J; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Flebbe DR; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Mychalowych A; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Lamb E; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Davis-Gardner ME; Department of Pediatrics, Center for Childhood Infections and Vaccines of Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, GA, USA.
  • Burnett MR; Emory Vaccine Center, Emory University, Atlanta, GA, USA.
  • Serebryannyy LA; Emory National Primate Research Center, Atlanta, GA, USA.
  • Lin BC; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Ziff ZE; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Maule E; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Carroll R; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Naisan M; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Jethmalani Y; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Pessaint L; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Todd JM; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Doria-Rose NA; Bioqual, Inc., Rockville, MD, USA.
  • Case JB; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Dmitriev IP; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Kashentseva EA; Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
  • Ying B; Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA.
  • Dodson A; Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA.
  • Kouneski K; Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
  • O'Dell S; Bioqual, Inc., Rockville, MD, USA.
  • Wali B; Bioqual, Inc., Rockville, MD, USA.
  • Ellis M; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Godbole S; Department of Pediatrics, Center for Childhood Infections and Vaccines of Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, GA, USA.
  • Laboune F; Emory Vaccine Center, Emory University, Atlanta, GA, USA.
  • Henry AR; Emory National Primate Research Center, Atlanta, GA, USA.
  • Teng IT; Department of Pediatrics, Center for Childhood Infections and Vaccines of Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, GA, USA.
  • Wang D; Emory Vaccine Center, Emory University, Atlanta, GA, USA.
  • Wang L; Emory National Primate Research Center, Atlanta, GA, USA.
  • Zhou Q; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Zouantchangadou S; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Van Ry A; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Lewis MG; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Andersen H; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Kwong PD; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Curiel DT; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Roederer M; Bioqual, Inc., Rockville, MD, USA.
  • Nason MC; Bioqual, Inc., Rockville, MD, USA.
  • Foulds KE; Bioqual, Inc., Rockville, MD, USA.
  • Suthar MS; Bioqual, Inc., Rockville, MD, USA.
  • Diamond MS; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Douek DC; Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA.
  • Seder RA; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Nat Immunol ; 25(10): 1913-1927, 2024 Oct.
Article en En | MEDLINE | ID: mdl-39227514
ABSTRACT
A mucosal route of vaccination could prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication at the site of infection and limit transmission. We compared protection against heterologous XBB.1.16 challenge in nonhuman primates (NHPs) ~5 months following intramuscular boosting with bivalent mRNA encoding WA1 and BA.5 spike proteins or mucosal boosting with a WA1-BA.5 bivalent chimpanzee adenoviral-vectored vaccine delivered by intranasal or aerosol device. NHPs boosted by either mucosal route had minimal virus replication in the nose and lungs, respectively. By contrast, protection by intramuscular mRNA was limited to the lower airways. The mucosally delivered vaccine elicited durable airway IgG and IgA responses and, unlike the intramuscular mRNA vaccine, induced spike-specific B cells in the lungs. IgG, IgA and T cell responses correlated with protection in the lungs, whereas mucosal IgA alone correlated with upper airway protection. This study highlights differential mucosal and serum correlates of protection and how mucosal vaccines can durably prevent infection against SARS-CoV-2.
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Inmunoglobulina A / Inmunización Secundaria / Vacunas contra la COVID-19 / SARS-CoV-2 / COVID-19 / Anticuerpos Antivirales Límite: Animals / Female / Humans Idioma: En Año: 2024 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Inmunoglobulina A / Inmunización Secundaria / Vacunas contra la COVID-19 / SARS-CoV-2 / COVID-19 / Anticuerpos Antivirales Límite: Animals / Female / Humans Idioma: En Año: 2024 Tipo del documento: Article